Obesity and drug dosing: acyclovir study seeks better fit

NCT ID NCT02879630

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a special weight-based dose of the antiviral drug acyclovir works properly in people with obesity. Researchers enrolled 13 hospitalized patients (10 obese and 3 non-obese) who were already receiving acyclovir as part of their care. They took blood samples over 12 hours to measure how the drug behaves in the body. The goal is to improve dosing guidelines for obese patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
acyclovir
What this could lead to
If successful, this could help doctors find the right acyclovir dose for obese patients, improving treatment safety and effectiveness.
What could go wrong
This is a very small study with only 13 participants, so results may not apply to everyone. It only measures drug levels, not actual health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West Virginia University Hospitals

    Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.